We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PTX market cap is 31.41M. The company's latest EPS is AUD -0.0087 and P/E is -4.60.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 1.65M | 1.08M | 1.24M | 1.89M | 2.43M |
| Operating Income | -3.9M | -3.42M | -4.19M | -5.21M | -7.46M |
| Net Income | -3.8M | -3.32M | -4.15M | -5.12M | -7.01M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 15.01M | 12.07M | 20.97M | 17.62M | 28.11M |
| Total Liabilities | 686k | 884k | 540k | 856k | 2.03M |
| Total Equity | 14.32M | 11.19M | 20.43M | 16.76M | 26.08M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -4.2M | -2.32M | -3.97M | -4.31M | -6.19M |
| Investing | N/A | N/A | -2k | -4k | N/A |
| Financing | 8.37M | N/A | 12.75M | 428k | -172k |
| Market Cap | 31.41M |
| Price to Earnings Ratio | -4.60 |
| Price to Sales Ratio | 13.33 |
| Price to Cash Ratio | 5.48 |
| Price to Book Ratio | 1.24 |
| Dividend Yield | - |
| Shares Outstanding | 805.32M |
| Average Volume (1 week) | 821.16k |
| Average Volume (1 Month) | 864.62k |
| 52 Week Change | -52.44% |
| 52 Week High | 0.105 |
| 52 Week Low | 0.038 |
| Spread (Intraday) | 0 (2.5%) |
| Company Name | Prescient Therapeutics Limited |
| Address |
level 4 melbourne, victoria 3205 |
| Website | https://www.ptxtherapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
